The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (62.67) USD. With the latest stock price at 2.02 USD, the upside of Immunitybio Inc based on DCF is -3202.3%.
Based on the latest price of 2.02 USD and our DCF valuation, Immunitybio Inc (IBRX) is a sell. selling IBRX stocks now will result in a potential gain of 3202.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 7.2% - 8.7% | 7.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (108.74) - (44.96) | (62.67) |
| Upside | -5483.2% - -2325.8% | -3202.3% |